HIV infection and lipodystrophy

Progress in Cardiovascular Diseases

Volumn 45, Issue 4, 2003, Pages 269-284

  Kotler, Donald P ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ARTHRALGIA; BODY DISTRIBUTION; BODY FAT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; JOINT STIFFNESS; LIPID STORAGE; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREVALENCE; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

EID: 0037217766     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2003.2     Document Type: Review

References (81)

1. Kotler DP: Nutritional alterations associated with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 25:S81-S87, 2000
2. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860, 1998
3. Silva M, Skolnik PR, Gorbach SL, et al: The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12:1645-1651, 1998
4. Carr A, Samaras K, Burton S, et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58, 1998
5. Miller KD, Jones E, Yanovski JA, et al: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871-875, 1998
6. van der Valk M, Bisschop PH, Romijn JA, et al: Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15:2093-2100, 2001
7. Henry K, Melroc H, Huebsch J, et al: Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328, 1998
8. Vague J: The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 4:20-23, 1956
9. Engelson EE, Kotler DP, Tan YX, et al: Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 69:1162-1169, 1999
10. Dong KL, Bausserman LL, Flynn MM, et al: Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr Hum Retrovirol 21:107-113, 1991
11. Lo JC, Mulligan K, Tai VW, et al: "Buffalo hump" in men with HIV-1 infection. Lancet 351:867-870, 1998
12. Lichtenstein KA, Ward DJ, Moorman AC, et al: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15:1389-1398, 2001
13. Raghavan S, Aidary AH, Lester K, et al: Gender differences in prevalence of body habitus changes and metabolic complications in HIV+ African American and Latino individuals from Harlem. Program of the 7th Conference on Retroviruses and Opportunistic Infections (abstr 27)
14. Kotler DP, Lopes J, Engelson ES, et al: Interactions among sex, HIV infection, and fat redistribution. AIDS Read 10:589-594, 2000
15. Muurahainen N, Santos G, Kleintop M, et al: Gender differences in HIV-associated adipose redistribution syndrome (HARS): An update. Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco, CA (abstr 26)
16. Arpadi SM, Cuff PA, Horlick M, et al: Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percent age at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr Hum Retrovirol 27:30-34, 2001
17. Mulligan K, Grunfeld C, Tai VW, et al: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 23:35-43, 2000
18. Purnell JQ, Zambon A, Knopp RH, et al: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57, 2000
19. Grunfeld C, Kotler DP, Hamadeh R, et al: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 86:27-31, 1989
20. Grunfeld C, Kotler DP, Shigenga JK, et al: Circulating interferon alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90:154-162, 1991
21. van der Valk M, Kastelein JJ, Murphy RL, et al: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15:2407-2414, 2001
22. Noor MA, Lo JC, Mulligan K, et al: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15:F11-F18, 2001
23. Noor MA, Seneviratne T, Aweeka FT, et al: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 16:F1-F8, 2002
24. Murata H, Hruz PW, Mueckler M: Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16:859-863, 2002
25. Duong M, Petit JM, Piroth L, et al: Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 27:245-250, 2001
26. Meininger G, Hadigan C, Laposata M, et al: Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51:260-266, 2002
27. Sekhar RV, Jahoor F, White AC, et al: Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol 283: E332-E337, 2002
28. Meininger G, Hadigan C, Rietschel P, et al: Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 76:460-465, 2002
29. Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 13:2493-2505, 1999
30. Grunfeld C: Fat redistribution and metabolic abnormalities. Program and abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain (abstr TuOr158)
31. Bradford-Hill A: The environment and disease: Association or causation. Proc R Soc Med 58:295-301, 1965
32. Gervasoni C, Ridolfo A, Trifiro G, et al: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13:465-471, 1999
33. Saint-Marc T, Partisani M, Poizot-Martin I, et al: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13:1659-1716, 1999
34. Nolan D, John M, Mallal S: Antiretoviral therapy and the lipodystrophy syndrome, part 2: Concepts in aetiopathogenesis. Antiviral Ther 6:145-160, 2001
35. Dube MP, Qian D, Edmondson-Melancon H, et al: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 35:475-481, 2002
36. Liang JS, Distler O, Cooper DA, et al: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7:1327-1331, 2001
37. John M, Moore CB, James IR, et al: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15:717-723, 2001
38. Brinkman K, Smeitink JA, Romijn JA, et al: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112-1115, 1999
39. Shikuma CM, Hu N, Milne C, et al: Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15:1801-1809, 2001
40. Ledru E, Christeff N, Patey O, et al: Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 95:3191-3198, 2000
41. Mynarcik DC, McNurlan MA, Steigbigel RT, et al: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr Hum Retrovirol 25:312-321, 2000
42. Johnson JA, Albu JB, Engelson ES, et al: Studies of subcutaneous adipose tissue (SAT) in HIV+ subjects with and without lipodystrophy. Program and abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain (abstr ThPeB7357)
43. Bentata M, Mansouri R, Honore P, et al: Could antihepatitis C virus treatment with interferon and ribavirin enhance or endure lipoatrophy in patients previously treated with anti-HIV multitherapy? Program and abstracts of the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, October 23-26, 2001, Athens, Greece. Antiviral Ther 6:27, 2001 (abstr 35, suppl 4)
44. Taskinen M, Saarinen-Pihkala UM, Hovi L, et al: Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 356:993-997, 2000
45. Collins E, Wagner C, Walmsley S: Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 10:546-550, 2000
46. Ammassari A, Murri R, Pezzotti P, et al: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 28:445-449, 2001
47. Mary-Krause M, Cotte L, Partisani M, et al: Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL (abstr 657)
48. Klein D, Hurley LB, Quesenberry CP Jr, et al: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr Hum Retrovirol 30:471-477, 2002
49. Currier J, Boyd F, Burtcel B, et al: Accelerated atherosclerosis in men infected with HIV. Antiviral Ther 6:36, 2001 (abstr 49, suppl 4)
50. Bozzette SA, Carpenter A, Bommakanty U, et al: Cardio- and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,776 US veterans. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA (abstr LB9)
51. Barbaro G, Di Lorenzo G, Gianaspro G, et al: Incidence of coronary artery disease in HIV-infected patients or not protease inhibitors: A randomized, multicenter trial. Program and abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain (abstr WeOrB1307)
52. Woolley IJ, Johnsen SP, Sorensen HT, et al: Cardiovascular events in the MACS cohort and prior prophylaxis with macrolides for mycobacterium avium complex. Program and abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain (abstr ThPeB7282)
53. Grinspoon S, Corcoran C, Miller K, et al: Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 82:1332-1337, 1997
54. Carr A, Hudson J, Chuah J, et al: The PIILR Study Group. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 15:1811-1822, 2001
55. Larsson B, Svardsudd K, Welin L, et al: Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 288:1401-1404, 1984
56. Zamboni M, Armellini F, Milani MP, et al: Evaluation of regional body fat distribution: Comparison between W/H ratio and computed tomography in obese women. J Intern Med 232:341-347, 1992
57. van der Kooy K, Leenen R, Seidell JC, et al: Abdominal diameters as indicators of visceral fat: Comparison between magnetic resonance imaging and anthropometry. Br J Nutr 70:47-58, 1993
58. Kotler DP, Rosenbaum K, Wang J, et al: Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 20:228-237, 1999
59. Armellini F, Zamboni M, Harris T, et al: Sagittal diameter minus subcutaneous thickness. An easy-to-obtain parameter that improves visceral fat prediction. Obes Res 5:315-320, 1997
60. Andrade S, Lan SJJ, Engelson ES, et al: Use of the Durnin-Womersley formulae to estimate changes in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr 75:587-592, 2002
61. Casey JL, Bouchard C, Teates CD, et al: The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. Obes Res 7:256-264, 1999
62. Martinez E, Bianchi L, Garcia-Viejo MA, et al: Sonographic assessment of regional fat in HIV-1-infected people. Lancet 356:1412-1413, 2000
63. Martinez E, Conget I, Lozano L, et al: Reversion of metabolic abnormalities after switching from HIV protease inhibitors to nevirapine. AIDS 13:805-810, 1999
64. Saint-Marc T, Touraine JL: The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 13:2188-2189, 1999
65. Carr A, Smith D, Workman C, et al: Switching stavudine or zidovudine to abacavir for HIV lipoatrophy: A randomised, controlled, open-label, multicentre, 24-week study. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA (abstr 32)
66. John M, James I, McKinnon E, et al: A randomised, controlled, open-label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA (abstr 700)
67. McComsey G, Lonergan T, Fisher R, et al: Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA (abstr 701)
68. Moyle GJ, Baldwin C, Gazzard BG: A randomised open label study of 3 substitution strategies in hypercholesterolemic persons virologically controlled on first line antiretroviral therapy (ART). Program and abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain (abstr ThPeB7322)
69. Moyle GJ, Lloyd M, Reynolds B, et al: Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15:1503-1508, 2001
70. Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 30:26-31, 2002
71. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16:569-577, 2002
72. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean noninsulindependent diabetic subjects. J Clin Endocrinol Metab 73:1294-1301, 1991
73. Hadigan C, Corcoran C, Basgoz N, et al: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284:472-477, 2000
74. Hadigan C, Meigs JB, Rabe J, et al: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 86:939-943, 2001
75. Mori Y, Murakawa Y, Okada K, et al: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912, 1999
76. Kohlroser J, Mathai J, Reichheld J, et al: Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272-276, 2000
77. Roubenoff R, Weiss L, McDermott A, et al: A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13:1373-1375, 1999
78. Johannsson G, Marin P, Lonn L, et al: Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82:727-734, 1997
79. Torres RA, Unger KW, Cadman JA, et al: Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART. AIDS 13:2479-2481, 1999
80. Wanke C, Gerrior J, Kantaros J, et al: Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099-2003, 1999
81. Engelson ES, Glesby MJ, Mendez D, et al: Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 30:379-391, 2002